Fast assessment of resistance to carbapenems and ciprofloxacin of clinical strains of Acinetobacter baumannii

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3609-3613

  Bou, Germán ^a   Otero, Fátima María ^a,b   Santiso, Rebeca ^a,b   Tamayo, María ^a,b   Fernández, María Del Carmen ^a   Tomás, María ^a   Gosálvez, Jaime ^c   Fernández, José Luis ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Centro Oncologico de Galicia   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; MEROPENEM; QUINOLONE;

ACCURACY; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CELL NUCLEUS; CLASSIFICATION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DNA FRAGMENTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; CARBAPENEMS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84867525156     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01675-12     Document Type: Article

References (22)

1. Bou G, Oliver A, Martínez-Beltrán J. 2000. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 44:1556-1561. (Pubitemid 30340794)
2. Cartelle M, et al. 2004. Risk factors for colonization and infection in a hospital outbreak caused by a strain of Klebsiella pneumoniae with reduced susceptibility to expanded-spectrum cephalosporins. J. Clin. Microbiol. 42:4242-4249. (Pubitemid 39296151)
3. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement. M100-S22, vol 32, no. 3. Clinical and Laboratory Standards Institute, Wayne, PA.
4. del Mar Tomas M, et al. 2005. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:5172-5175.
5. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939-951. (Pubitemid 350131182)
6. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392. (Pubitemid 351170804)
7. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. 2006. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J. Antimicrob. Chemother. 57:1251-1254. (Pubitemid 44644437)
8. Fernández JL, et al. 2008. DNA fragmentation in microorganisms assessed in situ. Appl. Environ. Microbiol. 74:5925-5933.
9. Gootz TD, Marra A. 2008. Acinetobacter baumannii: an emerging multi-drug-resistant threat. Expert Rev. Anti Infect. Ther. 6:309-325.
10. Hujer KM, et al. 2009. Rapid determination of quinolone resistance in Acinetobacter spp. J. Clin. Microbiol. 47:1436-1442.
11. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. 2002. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262-268. (Pubitemid 34754172)
12. Koch AL. 2003. Bacterial wall as target for attack: past, present, and future research. Clin. Microbiol. Rev. 16:673-687. (Pubitemid 37296555)
13. Kollef KE, et al. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281-287.
14. Merino M, et al. 2010. OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak. Antimicrob. Agents Chemother. 54:2724-2727.
15. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
16. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 362:1804-1813.
17. Santiso R, et al. 2009. Rapid and simple determination of ciprofloxacin resistance in clinical strains of Escherichia coli. J. Clin. Microbiol. 47:2593-2595.
18. Santiso R, et al. 2011. A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis. BMC Microbiol. 11:19. doi:10.1186/1471-2180-11-19.
19. Tamayo M, Santiso R, Gosálvez J, Bou G, Fernández JL. 2009. Rapid assessment of ciprofloxacin effect on chromosomalDNAfrom Escherichia coli with an in situ DNA fragmentation assay. BMC Microbiol. 9:69. doi:10.1186/1471-2180-9-69.
20. Vila J, Ruiz J, Goni P, Marcos A, Jimenez de Anta T. 1995. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 39:1201-1203.
21. Vila J, Ruiz J, Goni P, Jimenez de Anta T. 1997. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother. 39:757-762. (Pubitemid 27296416)
22. Wisplinghoff H, et al. 2003. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:177-180. (Pubitemid 36163847)